Case number 1:23-cv-00008
Taiho Pharmaceutical Co., Ltd. et al v. MSN Laboratories Private Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 17, 2023 | 15 | CONSENT to Jurisdiction by U.S. Magistrate Judge filed by MSN Laboratories Private Ltd., MSN Pharmaceuticals Inc., Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. Case reassigned to Magistrate Judge Jennifer L. Hall. Signed by Judge Colm F. Connolly on 11/17/2023. (nmf) (Entered: 11/17/2023) (6) |
| Apr 6, 2023 | 14 | STIPULATION and [Proposed] Order to Extend Certain Scheduling Order Deadlines by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 04/06/2023) (6) |
| Feb 28, 2023 | 13 | SCHEDULING & CONSOLIDATION ORDER: Civil Action No. 21-838-CFC shall be the lead case and all future filings shall be made in Lead Case No. 21-838-CFC ONLY. Joinder of Parties due by 6/16/2023. Amended Pleadings due by 6/16/2023. Fact Discovery completed by 9/29/2023. Expert Discovery due by 2/29/2024. Signed by Judge Colm F. Connolly on 2/28/2023. Associated Cases: 1:21-cv-00838-CFC, 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 02/28/2023) (25) |
| Feb 28, 2023 | N/A | Case associated with lead case: Create association to 1:21-cv-00838-CFC. ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 21-838-CFC ONLY. (nmf) (Entered: 02/28/2023) (0) |
| Feb 27, 2023 | 11 | Letter to The Honorable Colm F. Connolly from Steven J. Balick regarding the Parties' Joint Proposed Scheduling Order. (Balick, Steven) (Entered: 02/27/2023) (2) |
| Feb 27, 2023 | 12 | PROPOSED ORDER (Proposed Scheduling Order), by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd.. (Balick, Steven) (Entered: 02/27/2023) (25) |
| Feb 16, 2023 | 10 | SO ORDERED, re 9 STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023 filed by Natco Pharma Ltd., Natco Pharma, Inc. Signed by Judge Colm F. Connolly on 2/13/2023. (nmf) (Entered: 02/16/2023) (4) |
| Feb 10, 2023 | 9 | STIPULATION TO EXTEND TIME proposed scheduling order to February 27, 2023 - filed by Natco Pharma Ltd., Natco Pharma, Inc.. (Cragg, Tyler) (Entered: 02/10/2023) (4) |
| Jan 26, 2023 | 8 | SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc..MSN Laboratories Private Ltd. served on 1/25/2023, answer due 2/15/2023. (Balick, Steven) (Entered: 01/26/2023) (2) |
| Jan 25, 2023 | 7 | SUMMONS Returned Executed by Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc..MSN Pharmaceuticals Inc. served on 1/25/2023, answer due 2/15/2023. (Balick, Steven) (Entered: 01/25/2023) (2) |
| Jan 12, 2023 | 6 | ORDER, having been assigned these cases which are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before February 13, 2023, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines: ( Notice of Compliance deadline set for 2/13/2023.) Signed by Judge Colm F. Connolly on 1/12/2023. Associated Cases: 1:22-cv-01480-CFC, 1:22-cv-01611-CFC, 1:23-cv-00008-CFC(nmf) (Entered: 01/12/2023) (2) |
| Jan 11, 2023 | N/A | Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. (rjb) (Entered: 01/11/2023) (0) |
| Jan 3, 2023 | 1 | COMPLAINT for PATENT INFRINGEMENT filed against MSN Laboratories Private Ltd., and MSN Pharmaceuticals Inc. (Filing fee $ 402, receipt number ADEDC-4035334.) - filed by Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(mkr) (Entered: 01/03/2023) (Main Document) (24) |
| Jan 3, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (mkr) (Entered: 01/03/2023) (3) |
| Jan 3, 2023 | 3 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,960,004 B2. (mkr) (Entered: 01/03/2023) (1) |
| Jan 3, 2023 | 4 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd.; Corporate Parent Taiho Pharmaceutical Co., Ltd. for Taiho Oncology, Inc. filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Attachments: # 1 Disclosure Statement pursuant to Rule 7.1)(mkr) (Entered: 01/03/2023) (Main Document) (2) |
| Jan 3, 2023 | 5 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: December 1, 2022. Date of Expiration of Patent: February 3, 2037. (mkr) (Entered: 01/03/2023) (2) |
| Jan 3, 2023 | N/A | No Summons Issued. (mkr) (Entered: 01/03/2023) (0) |
| Jan 3, 2023 | 4 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Otsuka Holdings Co., Ltd. for Taiho Pharmaceutical Co., Ltd.; Corporate Parent Taiho Pharmaceutical Co., Ltd. for Taiho Oncology, Inc. filed by Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd. (Attachments: # 1 Disclosure Statement pursuant to Rule 7.1)(mkr) (Entered: 01/03/2023) (7.1) (2) |
| Jan 3, 2023 | 1 | COMPLAINT for PATENT INFRINGEMENT filed against MSN Laboratories Private Ltd., and MSN Pharmaceuticals Inc. (Filing fee $ 402, receipt number ADEDC-4035334.) - filed by Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(mkr) (Entered: 01/03/2023) (Exhibit A-B) (30) |
| Jan 3, 2023 | 1 | COMPLAINT for PATENT INFRINGEMENT filed against MSN Laboratories Private Ltd., and MSN Pharmaceuticals Inc. (Filing fee $ 402, receipt number ADEDC-4035334.) - filed by Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. (Attachments: # 1 Exhibits A-B, # 2 Civil Cover Sheet)(mkr) (Entered: 01/03/2023) (Civil Cover Sheet) (2) |
